Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden.
J Clin Pharmacol. 2013 Dec;53(12):1322-7. doi: 10.1002/jcph.174. Epub 2013 Sep 17.
To investigate the impact of interacting drugs on the dispensed doses of warfarin in the Swedish population. This was a retrospective, cross-sectional population based register study of patients being dispensed warfarin. Warfarin doses were estimated in different age groups, in men and women, and in patients using interacting drugs. The influence of interacting drugs on the dispensed warfarin dose was analyzed using multiple regression. All 143,729 patients dispensed warfarin were analyzed. The dispensed dose of warfarin was highest in patients 30-39 years old and decreased with age. Co-medication with carbamazepine, simvastatin, paracetamol, amiodarone, fluconazole, lactulose, or bezafibrate was associated with significant changes in dispensed warfarin doses, by +40%, -3.4%, -7.3%, -8.2%, -8.8%, -9.0%, and -9.7%, respectively. After adjustment for age and gender, sulfamethoxazole was also found to significantly alter the dispensed warfarin dose (-6.1%). We provide new support for the previous scarce evidence of interactions between warfarin and carbamazepine, bezafibrate, and lactulose. Initiation or discontinuation of bezafibrate or lactulose in a patient on warfarin should warrant close clinical monitoring. The marked increased warfarin requirement associated with carbamazepine use supports moving from a more conservative reactive towards a proactive strategy including preventive warfarin dose adjustments to avoid potential adverse effects.
研究相互作用的药物对瑞典人群中华法林配药剂量的影响。这是一项回顾性、横断面的基于人群的华法林配药患者登记研究。在不同年龄组、男性和女性以及使用相互作用药物的患者中估计华法林剂量。使用多元回归分析相互作用药物对华法林配药剂量的影响。所有 143729 名接受华法林配药的患者均进行了分析。30-39 岁患者的华法林配药剂量最高,随着年龄的增长而降低。与卡马西平、辛伐他汀、扑热息痛、胺碘酮、氟康唑、乳果糖或苯扎贝特合用与华法林配药剂量的显著变化相关,分别增加 40%、减少 3.4%、减少 7.3%、减少 8.2%、减少 8.8%、减少 9.0%和减少 9.7%。在调整年龄和性别后,发现磺胺甲恶唑也显著改变了华法林的配药剂量(减少 6.1%)。我们为华法林与卡马西平、苯扎贝特和乳果糖之间相互作用的先前稀缺证据提供了新的支持。在服用华法林的患者中开始或停止使用苯扎贝特或乳果糖时,应进行密切的临床监测。与卡马西平使用相关的华法林需求明显增加支持从更保守的反应性策略转变为更积极的策略,包括预防性华法林剂量调整,以避免潜在的不良反应。